other material
confidence high
sentiment positive
materiality 0.70
IO Biotech: Phase 3 melanoma trial continues; Phase 2 lung cancer shows 4 partial responses; $142.7M cash
IO Biotech, Inc.
- IDMC recommends Phase 3 melanoma trial continue without changes; enrolling at >80 sites globally.
- Initial Phase 2 basket data: 9 evaluable NSCLC patients: 4 partial responses, 4 stable disease, 1 progressive disease.
- New investigator-initiated study with Johns Hopkins for SCCHN expected H1 2023; total 4 IITs ongoing.
- Preliminary cash $142.7M at Dec 31, 2022; expected to fund operations into mid-2024.